SCHEMBL6778049

SCHEMBL6778049

CCC(C(=O)O)C(N)c1cc(C(C)C)cc(C(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 2/20 0.43
FABP4 P15090 2/20 0.43
SLC1A3 P43003 3/20 0.36
SLC1A2 P43004 3/20 0.36
SLC1A1 P43005 3/20 0.36
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
FABP5 Q01469 1/20 0.34
KIF11 P52732 1/20 0.33
GRIK1 P39086 2/20 0.33
GRIK2 Q13002 2/20 0.33
ACE P12821 2/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6378948 0.81 TPMT (0.39) SLC1A3SLC1A2SLC1A1RXRARXRB
SCHEMBL7356667 0.81 SLC1A1 (0.39) SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL6378952 0.81 TPMT (0.39) SLC1A3SLC1A2SLC1A1RXRARXRB
Hydrochloric Acid SCHEMBL6779507 0.79 TPMT (0.38) RXRARXRB
SCHEMBL6773156 0.79 KMT2A (0.40) RXRARXRB
SCHEMBL6780474 0.78 TTR (0.43) CRHBPCRHR2
SCHEMBL6779107 0.78 TTR (0.43)
SCHEMBL2298439 0.78 DPP4 (0.48) SLC1A3SLC1A2SLC1A1
SCHEMBL7426518 0.78 DPP4 (0.48) SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL6783703 0.77 TTR (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed